Newsroom

Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial

Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG). As the pioneer of ab interno canaloplasty, Sight Sciences is executing this IDE trial to seek FDA clearance for canal viscodilation alone as a MIGS procedure for adults with POAG

read more +
Sight Sciences to Report Third Quarter 2021 Financial Results on November 10, 2021

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / […]

read more +
Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference

MENLO PARK, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world’s most prevalent eye diseases, today announced plans to participate in the upcoming virtual Morgan Stanley Global Healthcare Conference. Sight Sciences’ management […]

read more +
Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement

Sight Sciences Seeks Injunction Related to Hydrus® Microstent’s Infringement

read more +
Sight Sciences Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma

Pioneering the Development of the Standalone MIGS Market, this Real-world data published in Clinical Ophthalmology show the safety, efficacy, and durability of effect of OMNI for use in a standalone procedure to reduce intraocular pressure and medication burden

read more +
Sight Sciences Reports Second Quarter 2021 Financial Results

MENLO PARK, Calif., August 12, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter ended June 30, 2021. Recent Business Highlights • Generated second quarter 2021 total revenue of […]

read more +
Sight Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021

MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the second quarter 2021 after the market close on Thursday, August 12, 2021. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. […]

read more +
Sight Sciences Announces Multiple Presentations at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting

New safety and efficacy data from both retrospective and prospective studies of the OMNI Surgical System and a prospective study of the TearCare System to be presented

read more +